D32.9
Conditions
Interventions
Group 1: Patients with an intracerebral meningioma confirmed histologically or resected, who are being treated as part of medical care.
Sponsors
Universitätsklinikum Gießen-Marburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients aged 18 years or older who have received a histological diagnosis of an intracranial meningioma through biopsy or resection are eligible for inclusion in the registry. Any additional treatment and/or follow-up is carried out according to the internal treatment algorithm (SOP Meningiomas), i.e., as part of standard care. Prospective data collection requires the patient’s informed consent, documented by a written declaration of consent for participation in the registry, including the collection, storage, processing, and transfer of data.
Exclusion criteria
Exclusion criteria: No exclusion criteria have been defined for this registry. Any patient who meets the above-mentioned inclusion criteria can be enrolled.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Progression-Free Survival (PFS - progression-free survival): Time from the start of radiotherapy until one of the following events occurs: - Tumor recurrence (after prior complete remission) - Tumor progression - New metastasis - Progression of an existing metastasis - Death (from any cause) - or the last documented follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| - Local recurrence-free survival (LRFS) - Overall survival (OS) - Side effects (toxicity, measured according to CTCAE v4.0/5.0) - Survival without severe toxicity - Quality of life (measured with EORTC QLQ-BN20) | — |
Countries
Germany
Contacts
Public ContactDaniel Habermehl
Universitätsklinikum Gießen-Marburg
Outcome results
None listed